Current Procedural Terminology, more commonly known as CPT®, refers to a medical code set created and maintained by the American Medical Association — and used by physicians, allied health professionals, nonphysician practitioners, hospitals, outpatient facilities, and laboratories to represent the services and procedures they perform. No provider of outpatient services gets paid without reporting the proper CPT® codes. [Description taken from this site](https://www.aapc.com/codes/cpt-codes-range/)] Current Procedural Terminology PyOBO v0.12.13-dev-207b46e9 on 2025-10-31T15:17:20.786178 by https://github.com/biopragmatics/pyobo/blob/main/src/pyobo/sources/cpt.py https://www.aapc.com https://edhub.ama-assn.org/ImageLibrary/Ed-Hub-Self-Serve/CPT-monogram.png Immune globulin (Ig), human, for intramuscular use IG Immune globulin (IgIV), human, for intravenous use IGIV Botulinum antitoxin, equine, any route botulinum antitoxin Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use CMVIG Diphtheria antitoxin, equine, any route diphtheria antitoxin Hepatitis B immune globulin (HBIg), human, for intramuscular use HBIG Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use RIG Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use RIG Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each RSV-MAb Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use CPT Code to be used for Beyfortus 0.5 mL RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use CPT Code to be used for Beyfortus 1.0 mL RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF Tetanus immune globulin (TIg), human, for intramuscular use TIG Vaccinia immune globulin, human, for intramuscular use vaccinia immune globulin Varicella-zoster immune globulin, human, for intramuscular use VZIG H1N1 immunization administration (intramuscular, intranasal), including counseling when performed Novel Influenza-H1N1-09, all formulations Adenovirus vaccine, type 4, live, for oral use adenovirus, type 4 Adenovirus vaccine, type 7, live, for oral use adenovirus, type 7 Anthrax vaccine, for subcutaneous or intramuscular use Anthrax, post-exposure prophylaxis Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use BCG Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use dengue fever tetravalent Chikungunya virus vaccine, live attenuated, for intramuscular use Chikungunya live attenuated vaccine, 0.5 mL, PF Chikungunya virus vaccine, recombinant, for intramuscular use Chikungunya, VLP, recombinant, 0.8 mL, PF Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use CPT Code to be used for JYNNEOS vaccine Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), for intramuscular use meningococcal B, OMV Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use meningococcal B, recombinant Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use CPT Code to be used for ACAM2000 vaccine Vaccinia (smallpox, mpox), live Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use Meningococcal oligosaccharide (MenACWY), (MenB), PF Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use cholera, live attenuated Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use Tick-borne encephalitis, inactivated, PF, 0.25mL Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use Tick-borne encephalitis, inactivated, PF, 0.5mL Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use influenza, intradermal, quadrivalent, preservative free Hepatitis A vaccine (HepA), adult dosage, for intramuscular use Hep A, adult Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use Hep A, ped/adol, 2 dose Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use Hep A, ped/adol, 3 dose Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use Hep A-Hep B Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use Meningococcal C/Y-HIB PRP Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use Hib (HbOC) Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use Hib (PRP-D) Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use Hib (PRP-OMP) Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use Hib (PRP-T) Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use HPV, quadrivalent Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use HPV, bivalent Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use HPV9 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use Influenza, adjuvanted, trivalent, PF Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use influenza, seasonal, intradermal, preservative free Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use Influenza, split virus, trivalent, PF Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use Influenza, split virus, trivalent, preservative Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use Influenza, split virus, trivalent, preservative Influenza virus vaccine, whole virus, for intramuscular or jet injection use influenza, whole Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use Influenza, live, trivalent, intranasal, PF Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use Influenza, MDCK, trivalent, PF Influenza, MDCK, trivalent, preservative Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use Influenza, high-dose, quadrivalent, PF Influenza, high-dose, trivalent, PF Influenza virus vaccine, pandemic formulation, H1N1 Novel Influenza-H1N1-09, all formulations Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use Novel Influenza-H1N1-09, nasal Lyme disease vaccine, adult dosage, for intramuscular use Lyme disease Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use Novel influenza-H1N1-09, preservative-free Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use Novel influenza-H1N1-09 Pneumococcal conjugate vaccine, 7 valent, for intramuscular use pneumococcal conjugate PCV 7 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use Pneumococcal conjugate PCV 13 Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use Influenza, live, quadrivalent, intranasal Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use Influenza, recombinant, trivalent, PF Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use Influenza, MDCK, quadrivalent, PF Rabies vaccine, for intramuscular use Rabies - IM Diploid cell culture Rabies - IM fibroblast culture Rabies vaccine, for intradermal use rabies, intradermal injection Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use CPT Code to be used for ABRYSVO RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use CPT Code to be Used for Arexvy RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use rotavirus, pentavalent Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use rotavirus, monovalent Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use Influenza, recombinant, quadrivalent, PF Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use RSV, mRNA, injectable, PF Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use Influenza, injectable,quadrivalent, preservative free, pediatric Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use Influenza, split virus, quadrivalent, PF Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use Influenza, split virus, quadrivalent, preservative Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use Influenza, split virus, quadrivalent, preservative Typhoid vaccine, live, oral typhoid, oral Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use typhoid, ViCPs Typhoid vaccine, heat- and phenol-inactivated (H-P), for subcutaneous or intradermal use typhoid, parenteral Typhoid vaccine, acetone-killed, dried (AKD), for subcutaneous use (U.S. military) typhoid, parenteral, AKD (U.S. military) Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use Influenza, adjuvanted, quadrivalent, PF Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use DTaP-IPV Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use DTaP,IPV,Hib,HepB Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use DTaP-Hib-IPV Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use DTaP DTaP, 5 pertussis antigens Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP), for intramuscular use DTP Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use DT (pediatric) Tetanus toxoid adsorbed, for intramuscular use tetanus toxoid, adsorbed Mumps virus vaccine, live, for subcutaneous use mumps Measles virus vaccine, live, for subcutaneous use measles Rubella virus vaccine, live, for subcutaneous use rubella Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use MMR Measles and rubella virus vaccine, live, for subcutaneous use M/R Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use MMRV Poliovirus vaccine, (any type[s]) (OPV), live, for oral use OPV, Unspecified Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use IPV Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use Beginning in 2005, this CPT code maps to TD preservative free. Remapped to CVX code 09 10/2021 to support active products mapped to that code. Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use Tdap Varicella virus vaccine (VAR), live, for subcutaneous use varicella Yellow fever vaccine, live, for subcutaneous use Yellow fever vaccine live - alt yellow fever live Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine (DTP-Hib), for intramuscular use DTP-Hib Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP/Hib), for intramuscular use DTaP-Hib Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use DTaP-Hep B-IPV Influenza virus vaccine influenza, unspecified formulation Cholera vaccine for injectable use cholera, unspecified formulation Rabies vaccine rabies, unspecified formulation Plague vaccine, for intramuscular use plague BCG vaccine BCG Hepatitis A vaccine Hep A, unspecified formulation Hepatitis B vaccine Hep B, unspecified formulation Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use pneumococcal polysaccharide PPV23 Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use meningococcal MPSV4 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use Meningococcal MCV4O meningococcal MCV4P Japanese encephalitis virus vaccine, for subcutaneous use Japanese encephalitis SC Zoster (shingles) vaccine (HZV), live, for subcutaneous injection zoster live Hemophilus influenza B Hib, unspecified formulation Japanese encephalitis virus vaccine, inactivated, for intramuscular use Japanese Encephalitis IM Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use HepB-CpG Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use Hep B, high-dosage, dialysis or IC Immunization, passive; immune serum globulin, human (ISG) IG, unspecified formulation Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use Hep B, adolescent or pediatric Hep B, adult Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use Hep B, adolescent or pediatric Hepatitis B vaccine, adolescent/high risk infant dosage, for intramuscular use Hep B, adolescent/high risk infant Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use Hep B, adult Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use Hep B, high-dosage, dialysis or IC Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use Hib-Hep B Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use zoster recombinant Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use Effective 1/1/2018 Influenza, MDCK, quadrivalent, preservative Zaire ebolavirus vaccine, live, for intramuscular use Ebola Zaire vaccine, live, recombinant, 1mL dose Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use HepB recombinant, 3-antigen, Al(OH)3 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use COVID-19 Vaccine - EUA authorized 12/11/2020 COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use COVID-19 Vaccine - BLA Licensed and EUA authorized COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use COVID-19 Vaccine - EUA submission withdrawn COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized 2/27/2021 COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use Original and Fall COVID-19 vaccine starting 2023 COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - EUA authorized for primary series and IC, EUA rescinded 8/31/202 for monovalent boosters COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorization rescinded 8/31/2022 for adult monovalent booster dose COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - EUA authorized, pediatric 5 yrs through 11 yrs dose requires dilution COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - EUA authorized for children under 5 yrs COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized for pediatric, EUA rescinded 8/31/2022 for adult monovalent booster dose COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use COVID-19 Vaccine - Potential EUA authorization booster dose COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized for ages 6 mo through 5 yrs COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster ages 12+ yrs COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 18+ yrs, potential EUA ages 6 yrs through 17 yrs COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized 8/31/2022 bivalent booster for ages 6 yrs through 11 yrs COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - Potential EUA authorization bivalent booster for ages 5 yrs through 11 yrs COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent booster (Moderna) for ages 6 mo through 5 yrs COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use COVID-19 Vaccine - EUA authorized 12/8/2022 bivalent vaccine (Pfizer) for ages 6 mo through 4 yrs COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Fall COVID-19 vaccine starting 2023 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Fall COVID-19 vaccine starting 2023 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Fall COVID-19 vaccine starting 2023 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use Fall COVID-19 vaccine starting 2023 COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use Fall COVID-19 vaccine starting 2023 COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL